FASE

July 28, 2023

Consolidated Financial Results for the 1st Quarter ended June 30, 2023 (Japanese Generally Accepted Accounting Principles)

| Name of company | Yakult Honsha C | Yakult Honsha Co., Ltd. | | | | |
|--|------------------|--------------------------------------|----------------|---------------------|--|--|
| Stock exchange listing | Prime Market in | Prime Market in Tokyo Stock Exchange | | | | |
| Code number | 2267 | | | | | |
| URL | https://www.yak | ult.co.jp | | | | |
| Representative | President and Re | presentative Director | Hiroshi Narita | | | |
| Contact person | Managing Execu | Managing Executive officer | | TEL +81-3-6625-8960 | | |
| Scheduled date of filing Statutory quarterly | financial report | August 9, 2023 | | | | |
| Scheduled date of payment of dividends | | _ | | | | |

Preparation of support documentation of results : Yes

Holding of briefing for analysts and institutional investors : Yes

(Figures less than 1 million yen have been rounded down) 0, 2023 (April 1, 2023 - June 30, 2023)

1. Consolidated financial results for the 1st quarter of FY2023, ended June 30, 2023 (April 1, 2023 - June 30, 2023)(1) Consolidated Financial Results (Accumulated)(Percentage figures presents year-on-year changes)

| | Net Sales | | Net Sales Operating Profit | | Ordinary Profit | | Profit attributable to owners of parent | |
|-----------|-------------|------|----------------------------|------|-----------------|------|--|-------|
| | million yen | % | million yen | % | million yen | % | million yen | % |
| 1Q FY2023 | 122,155 | 13.1 | 16,981 | 15.0 | 20,859 | 13.0 | 13,111 | 14.5 |
| 1Q FY2022 | 107,983 | 12.0 | 14,770 | 27.2 | 18,460 | 12.1 | 11,451 | (2.5) |

(Note) Comprehensive income for 1Q FY2023 29,320 million yen $\{(21.4)\%\}$ 1Q FY2022 37,286 million yen $\{67.0\%\}$

| | Basic earnings per Share | Diluted earnings per Share |
|-----------|--------------------------|----------------------------|
| | yen | yen |
| 1Q FY2023 | 84.01 | _ |
| 1Q FY2022 | 73.03 | _ |

(2) Consolidated Financial Position

| | Total Assets | Net Assets | Equity to Asset Ratio |
|-----------|--------------|-------------|-----------------------|
| | million yen | million yen | % |
| 1Q FY2023 | 763,990 | 567,785 | 67.7 |
| FY2022 | 749,419 | 545,496 | 66.5 |

(Ref.) Equity for 1Q FY2023 517,219 million yen FY2022 498,659 million yen

2. Dividends

| | Dividends per Share | | | | | | |
|------------|---------------------|----------|----------|----------|-------|--|--|
| | 1st Qtr. | 2nd Qrt. | 3rd Qrt. | Year End | Total | | |
| | yen | yen | yen | yen | yen | | |
| FY2022 | — | 45.00 | — | 45.00 | 90.00 | | |
| FY2023 | — | | | | | | |
| FY2023 | | 55.00 | _ | 28.00 | _ | | |
| (Forecast) | | 55.00 | | 20.00 | | | |

(Note) Revision of the latest dividend forecast : Yes

(Note) The Company resolved at a meeting of its Board of Directors held today to implement a 2-for-1 stock split of shares of common stock with an effective date of October 1, 2023. For this reason, the year-end dividend per share (projected) for the fiscal year ending March 31, 2024 is presented in an amount that takes the impact of this stock split into account. The year-end dividend per share (projected) for the fiscal year ending March 31, 2024 without considering the stock split would be 56 yen. For details, please refer to the "Notification Regarding Stock Split and Related Partial Amendment to Articles of Incorporation, Revision of Dividend Forecast, and Shareholder Benefit Program" released today.

3. Forecast for consolidated financial results for FY2023 (April 1, 2023 - March 31, 2024)

| | (Percentage figures presents year-on-year change | | | | | | | resents year-on-year changes) | |
|----------|--|------|-------------|-------|-----------------|------|------------------|-------------------------------|--------------------|
| | Net Sale | | Operating P | rofit | Ordinary Dr | ofit | Profit attributa | uble to | Basic earnings per |
| | Inet Sale | 5 | Operating F | 10111 | Ordinary Profit | | owners of parent | | Share |
| | million yen | % | million yen | % | million yen | % | million yen | % | yen |
| 2nd Qrt. | 261,500 | 12.3 | 37,000 | 4.8 | 44,500 | 6.0 | 27,500 | 2.2 | 176.20 |
| Annual | 531,000 | 9.9 | 75,500 | 14.3 | 91,000 | 16.7 | 58,500 | 15.5 | 187.42 |

(Note) Revision of the latest financial forecast : No

(Note) The impact of the stock split has been taken into account in the basic earnings per share in the forecast for consolidated financial results for FY2023 (full year). The forecast for basic earnings per share for FY2023 without considering the stock split would be 374.83 yen.

*Notes

- (1) Changes of important subsidiaries during the period : No (Change in specified subsidiary with change in scope of consolidation)
- (2) Special Accounting Treatment for Preparation of the Quarterly Consolidated Financial Statements : Yes (Note) Details are stated on pg. 9 under "Notes on Quarterly Consolidated Financial Statements."

(3) Change in accounting policies and estimates, correction of prior period errors

| (a) | Change in accounting policy with revision of accounting standard : | No |
|-----|--|----|
| (b) | Change in account policy other than (a) : | No |
| (c) | Change in accounting estimates : | No |
| (d) | Correction of prior period errors : | No |

(d) Correction of prior period errors :

(4) Shares issued (common stock)

| rter) |
|-------|
| |
| |
| rte |

* This financial report is not included in quarterly reviews by our external auditors.

* Explanation for the appropriate use of the financial forecast and other comments

Note concerning statements about the future, etc.

The statements about the future, including earnings projections, contained in this report are based on information currently available as well as certain assumptions considered reasonable. Actual results may vary considerably from these projections owing to a range of factors.

Assumptions upon which the forecast is based and notes on the use of the forecast are stated on pg. 4 under "Disclaimer on Future Outlook Including Consolidated Financial Results Forecast."

Procedure for obtaining supplementary information on financial results

We plan to hold a conference call for analysts and institutional investors on July 28, 2023. Materials used in the conference call will be posted on the company's website.

Table of Contents

| 1. Qualitative Information Regarding Quarterly Consolidated Financial Results |
|---|
| (1) Business Performance Overview |
| (2) Financial Position |
| (3) Disclaimer on Future Outlook Including Consolidated Financial Results Forecast 4 |
| |
| 2. Quarterly Consolidated Financial Statements and Notes |
| (1) Quarterly Consolidated Balance Sheet |
| (2) Quarterly Consolidated Statements of Income and Comprehensive Income |
| Quarterly Consolidated Statement of Income7 |
| Quarterly Consolidated Statement of Comprehensive Income |
| (3) Notes on Quarterly Consolidated Financial Statements |
| (Notes Related to Going Concern Assumption)9 |
| (Special Accounting Treatment for Preparation of the Quarterly Consolidated Financial |
| Statements)9 |
| (Segment Information) 10 |
| (Significant Subsequent Events)12 |

1. Qualitative Information Regarding Quarterly Consolidated Financial Results

(1) Business Performance Overview

1 Performance Overview

During the first quarter of the fiscal year ending March 31, 2024, despite a gradual recovery in economic conditions, partly as the result of the effects of various policies, the Japanese economy remained susceptible to downward risks due to global monetary tightening and other factors and to the impacts of rises in the cost of living and other factors.

Against this background, the Yakult Group worked to build awareness and understanding of the probiotics that constitute the bedrock of our operations, while striving to communicate the superiority of our products. Guided by our long-term vision, Yakult Group Global Vision 2030, we pursued business activities and sought to improve our performance with the aim of evolving into a healthcare company that continues to contribute to the health of people around the world.

Following these efforts, consolidated net sales for the three months of this fiscal year rose 13.1% from the same period of the previous year to 122,115 million yen. Operating profit increased 15.0% to 16,981 million yen, while ordinary profit increased 13.0% to 20,859 million yen. Profit attributable to owners of parent increased 14.5% to 13,111 million yen.

2 Overview by Segment Food and Beverages (Japan)

In dairy products, Yakult focused on broadening recognition of the science behind its proprietary living *Lactobacillus casei* strain Shirota¹ and *Bifidobacterium breve* strain Yakult by utilizing evidence to conduct grassroots value dissemination initiatives.

In our home delivery channel, we implemented initiatives to encourage customers to drink the fermented milk drinks *Yakult 1000* and the *Yakult 400W*, linking them to the roll-out of advertising. To strengthen our home delivery organization, we pressed ahead with efforts to conduct recruitment activities and create convenient working conditions for Yakult Ladies.

As for the retail store channel, we worked to improve visibility in store, focusing on the fermented milk drinks *Yakult 1000* and the *New Yakult* series, in our efforts to increase revenue.

In product-specific initiatives, we addressed rising demand for *Yakult 1000* and *Y1000* by increasing production capacity for both products. We will continue taking action to ensure stable supply going forward.

In other beverages, in April, we expanded the sales regions of *Kan Fine*, a food with functional claims that contains an effective quantity of anthocyanin derived from purple sweet potato and that assists with lowering the level of the enzymes, AST and γ -GTP, related to liver function, and worked to increase sales.

As a result of these efforts, consolidated net sales for the Food and Beverages (Japan) segment increased 14.5% from the same period of the previous fiscal year, totaling 63,887 million yen.

Food and Beverages (Overseas)

Yakult's operations outside Japan commenced in March 1964 with the establishment of Yakult Taiwan Co., Ltd., and now the manufacture and sale of *Yakult* outside of Japan spans 39 countries and regions centered around 29 companies and one research center, with average daily bottle sales of approximately 30.57 million bottles in June 2023.

a. The Americas

In the Americas, *Yakult* and other products are manufactured and sold by Yakult S/A Ind. E Com. (Brazil), Yakult S.A. De C.V. (Mexico), and Yakult U.S.A. Inc.

At Yakult U.S.A. Inc., boosting support for sales through publicity campaigns and other initiatives, as well as making efforts to increase the number of stores stocking our products resulted in a steady increase in sales figures.

In other regions within the Americas, we strived to increase revenue by reinforcing the sales networks for both the home delivery and retail store sales channels.

As a result of these efforts, consolidated net sales in the Food and Beverages (The Americas) segment increased

¹ Classified as *Lacticaseibacillus paracasei* strain Shirota as of April 2020.

34.4% from the same period of the previous year to 18,652 million yen.

b. Asia and Oceania

In Asia and Oceania, *Yakult* and other products are manufactured and sold by Hong Kong Yakult Co., Ltd.; Yakult (Singapore) Pte. Ltd.; PT. Yakult Indonesia Persada; Yakult Australia Pty. Ltd.; Guangzhou Yakult Co., Ltd.; Yakult (Malaysia) Sdn. Bhd.; Shanghai Yakult Co., Ltd.; Beijing Yakult Co., Ltd.; Yakult (China) Corporation; Yakult Vietnam Co., Ltd.; and Yakult Danone India Pvt. Ltd.; among others. In addition, Yakult Middle East FZCO imports *Yakult* and other products for sale.

At Yakult Vietnam Co., Ltd., as the result of efforts to enhance the home delivery organization and increase the number of stores stocking our products, the monthly average number of bottles sold per day in April was the highest on record.

Yakult (China) Corporation established the Xuzhou Branch in Xuzhou, Jiangsu Province and began selling *Yakult*, *Yakult Light*, and *Yakult 50 Billion Light* in the retail store channel in June. This brought the number of sales location in China to 51.

As a result of the above, consolidated net sales in the Food and Beverages (Asia and Oceania) segment rose 8.7% from the same period of the previous year to 31,827 million yen.

c. Europe

In Europe, *Yakult* and other products are manufactured by Yakult Europe B.V., and sold by Yakult Nederland B.V., Yakult Belgium N.V./S.A., Yakult Europe B.V., Yakult UK Ltd., Yakult Deutschland GmbH, Yakult Oesterreich GmbH, and Yakult Italia S.r.l.

In this region, taking advantage of heightened health consciousness, we aimed for sustainable growth by conducting sales activities tailored to each individual country's market.

Yakult UK Ltd. began selling Yakult Plus in the retail store channel in April.

Meanwhile, the prolongation of the conflict between Russia and Ukraine means that, although we do not operate in either country, we will continue to pay close attention to the impact of the conflict on Europe as a whole.

As a result of these efforts, consolidated net sales in the Food and Beverages (Europe) segment increased 2.5% from the same period of the previous year to 2,638 million yen.

Others

This segment encompasses Yakult's cosmetics manufacturing and sales, pharmaceuticals manufacturing and sales, and its professional baseball team operations.

In our cosmetics operations, we worked to help customers realize their internal and external beauty, and to increase the number of regular users of our cosmetics by focusing on initiatives to disseminate the value of our proprietary moisturizing agent S.E. (Shirota Essence), which is the result of our extensive research on lactic acid bacteria since the Company's foundation.

As specific examples of such activities, in the *Lactdew* series of basic skin care products, we released a revamped version of *Lactdew S.E. Lotion 1*, which offers a lightly moisturized feel. We also rolled out a brand-boosting campaign for our *Parabio* series of high-performance basic skin care products in an effort to encourage regular use of the products in the series.

In our pharmaceuticals operations, we promoted awareness and the proper use of our products, particularly those specializing in oncology and related fields. Regarding our mainstay, the antineoplastic drug *Elplat*, while medical institutions are increasingly switching to available generic versions in line with government policy, we leveraged our ability to provide relevant information about it, a Company strength as the developer of the original drug.

However, our revenue was impacted by revisions to National Health Insurance drug prices in April 2023, which reduced prices for most of Yakult's pharmaceutical products.

In our professional baseball operations, we improved the various fan service engagements at Jingu Stadium and disseminated a range of information in our efforts to increase attendance and revenue.

As a result of the above factors, consolidated net sales in the Others segment fell 12.9% from the same period of the previous year to 8,281 million yen.

(2) Financial Position

Total assets at the fiscal quarter-end amounted to 763,990 million yen, an increase of 14,570 million yen compared to the previous fiscal year-end, three months prior.

Net assets increased 22,288 million yen from the previous fiscal year-end to 567,785 million yen. The main factors were an increase in foreign currency translation adjustments due to a weaker yen and an increase in retained earnings due to quarterly profit attributable to owners of parent.

The equity to asset ratio was 67.7%, an increase of 1.2 percentage point from the previous fiscal year-end.

(3) Disclaimer on Future Outlook Including Consolidated Financial Results Forecast

The aforementioned forecast is based on the information available to management at the time of announcement. Actual operating results may differ from these projections due to various factors in the future.

We have made no changes to our financial results forecasts from those announced on May 12, 2023.

2. Quarterly Consolidated Financial Statements and Notes

(1) Quarterly Consolidated Balance Sheet

| | | (Millions of yen) |
|---------------------------------------|---|--|
| | Fiscal year 2022 As of March 31, 2023 | Fiscal year 2023 As of June 30, 2023 |
| ssets | | |
| Current Assets | | |
| Cash and Deposits | 241,185 | 234,581 |
| Notes and accounts receivable-trade | 60,139 | 65,170 |
| Merchandises and Finished goods | 10,383 | 11,071 |
| Work in process | 2,578 | 2,370 |
| Raw materials and supplies | 23,741 | 25,007 |
| Others | 16,452 | 19,427 |
| Allowance for doubtful accounts | (285) | (310 |
| Total current assets | 354,195 | 357,318 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Buildings and structures, net | 93,771 | 93,890 |
| Others, net | 131,351 | 135,900 |
| Total Property, plant and equipment | 225,122 | 229,802 |
| Intangible assets | | · · · · · · · · · · · · · · · · · · · |
| Software | 2,269 | 2,434 |
| Others | 3,300 | 3,338 |
| Total intangible assets | 5,570 | 5,773 |
| Investments and other assets | | |
| Investment securities | 66,000 | 72,379 |
| Shares of subsidiaries and associates | 79,673 | 79,060 |
| Others | 18,942 | 19,739 |
| Allowance for doubtful accounts | (85) | (84 |
| Total investments and other assets | 164,531 | 171,095 |
| Total non-current assets | 395,224 | 406,671 |
| Total assets | 749,419 | 763,990 |

| | Fiscal year 2022 As of | (Millions of yen) Fiscal year 2023 As of |
|---|---------------------------|--|
| | As of March 31, 2023 | As of June 30, 2023 |
| Liabilities | , | , |
| Current liabilities | | |
| Notes and accounts payable-trade | 28,958 | 25,563 |
| Short-term loans payable | 3,208 | 3,314 |
| Current portion of long-term loans payable | 45,839 | 45,814 |
| Income taxes payable | 11,539 | 5,827 |
| Provision for bonuses | 6,784 | 4,180 |
| Others | 51,315 | 53,383 |
| Total current liabilities | 147,645 | 138,084 |
| Non-current liabilities | | |
| Long-term loans payable | 14,559 | 13,243 |
| Provision for directors' retirement benefits | 360 | 220 |
| Net defined benefit liability | 4,279 | 4,331 |
| Asset retirement obligations | 1,693 | 1,694 |
| Others | 35,384 | 38,630 |
| Total non-current liabilities | 56,277 | 58,120 |
| Total liabilities | 203,922 | 196,204 |
| Met assets | | |
| Shareholders' equity | | |
| Capital stock | 31,117 | 31,117 |
| Capital surplus | 41,572 | 41,572 |
| Retained earnings | 484,243 | 490,331 |
| Treasury shares | (81,927) | (81,927) |
| Total shareholders' equity | 475,006 | 481,094 |
| Accumulated other comprehensive income | | |
| Valuation difference on available-for-sale securities | 20,417 | 24,841 |
| Foreign currency translation adjustment | 3,991 | 11,995 |
| Remeasurements of defined benefit plans | (756) | (711) |
| Total accumulated other comprehensive income | 23,652 | 36,124 |
| Non-controlling interests | 46,837 | 50,565 |
| Total net assets | 545,496 | 567,785 |
| Total liabilities and net assets | 749,419 | 763,990 |

(2) Quarterly Consolidated Statement of Income and Comprehensive Income

Quarterly Consolidated Statement of Income

| | | (Millions of yen) |
|---|---|--|
| | Previous period From April 1, 2022 to June 30, 2022 | Current period From April 1, 2023 to June 30, 2023 |
| Net sales | 107,983 | 122,115 |
| Cost of sales | 42,531 | 49,425 |
| Gross profit | 65,452 | 72,689 |
| Selling, general and administrative expenses | 50,681 | 55,708 |
| Operating profit | 14,770 | 16,981 |
| Non-operating income | | |
| Interest income | 1,078 | 2,426 |
| Dividend income | 980 | 1,030 |
| Share of profit of entities accounted for using equity method | 850 | 412 |
| Others | 1,178 | 550 |
| Total non-operating income | 4,088 | 4,419 |
| Non-operating expenses | | |
| Interest expenses | 177 | 152 |
| Foreign exchange losses | - | 158 |
| Others | 220 | 231 |
| Total non-operating expenses | 398 | 542 |
| Ordinary profit | 18,460 | 20,859 |
| Extraordinary income | | |
| Gain on sales of non-current assets | 128 | 49 |
| Others | 30 | - |
| Total extraordinary income | 158 | 49 |
| Extraordinary losses | | |
| Loss on sales of non-current assets | 1 | 1 |
| Loss on retirement of non-current assets | 61 | 37 |
| Others | 0 | 0 |
| Total extraordinary losses | 63 | 39 |
| Profit before income taxes | 18,555 | 20,869 |
| Income taxes | 5,952 | 6,393 |
| Profit | 12,602 | 14,475 |
| Profit attributable to non-controlling interests | 1,151 | 1,364 |
| Profit attributable to owners of parent | 11,451 | 13,111 |

Quarterly Consolidated Statement of Comprehensive Income

| | | (Millions of yen) |
|---|---|--|
| | Previous period From April 1, 2022 to June 30, 2022 | Current period From April 1, 2023 to June 30, 2023 |
| Profit | 12,602 | 14,475 |
| Other comprehensive income | | |
| Valuation difference on available-for-sale securities | 925 | 4,420 |
| Foreign currency translation adjustment | 23,801 | 9,899 |
| Remeasurements of defined benefit plans, net of tax | 57 | 48 |
| Share of other comprehensive income of entities accounted for using equity method | (100) | 477 |
| Total other comprehensive income | 24,684 | 14,845 |
| Comprehensive income | 37,286 | 29,320 |
| Comprehensive income attributable to: | | |
| Owners of parent | 32,349 | 25,583 |
| Non-controlling interests | 4,937 | 3,737 |

(3) Notes on Quarterly Consolidated Financial Statements

(Notes Related to Going Concern Assumption) None.

(Special Accounting Treatment for Preparation of the Quarterly Consolidated Financial Statements) Calculation of Tax Expenses

Tax expenses for the Company and its consolidated subsidiaries in Japan are calculated by multiplying income before income taxes for the third quarter under review by the reasonably estimated effective tax rate after applying tax effect accounting to the income before income taxes for the current consolidated fiscal year, including the third quarter under review.

In addition, income taxes-deferred are included in income taxes.

(Segment Information)

- I The first quarter of FY2022 (April 1 to June 30, 2022)
- 1. Net sales, profit (loss), and disaggregated revenue in each reportable segment

(Millions of yen)

| | Food and Beverages | | | |
|--|--------------------|--------------|---------------------|--------|
| | Japan | The Americas | Asia and Oceania | Europe |
| Net sales Revenue from contracts with customers Other revenues | 53,297 | 13,878 | 29,282 | 2,574 |
| Net sales to external customers Intersegment net sales or transfers | 53,297 2,514 | 13,878 | 29,282 | 2,574 |
| Total | 55,812 | 13,878 | 29,282 | 2,574 |
| Segment profit (loss) | 10,484 | 3,778 | 3,795 | 98 |

| | Others | Adjustments | Consolidated results |
|--|--------------|-------------|----------------------|
| Net sales Revenue from contracts with customers Other revenues | 8,949 — | | 107,983 |
| Net sales to external customers Intersegment net sales or transfers | 8,949 558 | (3,072) | 107,983 |
| Total | 9,507 | (3,072) | 107,983 |
| Segment profit (loss) | 1,177 | (4,564) | 14,770 |

Notes: 1. Adjustments are as follows.

The (4,564) million yen adjustment in segment profit (loss) includes (2,799) million yen of corporate expenses not allocated to specific reportable segments. Corporate expenses include those of administrative divisions of the Company, such as the general affairs department, that cannot be attributed to any specific reportable segments.

- 2. Segment profits are adjusted with operating profit under the quarterly consolidated statement of income.
- 3. Countries / regions in each geographic segment outside Japan.
- (1) The Americas Mexico, Brazil, The United States of America
- (2) Asia and Oceania Hong Kong, China, Indonesia, Singapore, Malaysia, Australia, India,

Vietnam, The United Arab Emirates, Myanmar

(3) Europe The Netherlands, The United Kingdom, Germany, Belgium, Austria, Italy

II The third quarter of FY2023 (April 1 to June 30, 2023)

Net sales, profit (loss), and disaggregated revenue in each reportable segment

(Millions of yen)

| | Food and Beverages | | | |
|---------------------------------------|--------------------|--------------|---------------------|--------|
| | Japan | The Americas | Asia and Oceania | Europe |
| Net sales | | | | |
| Revenue from contracts with customers | 61,299 | 18,652 | 31,827 | 2,638 |
| Other revenues | _ | _ | _ | _ |
| Net sales to external customers | 61,299 | 18,652 | 31,827 | 2,638 |
| Intersegment net sales or transfers | 2,587 | — | _ | — |
| Total | 63,887 | 18,652 | 31,827 | 2,638 |
| Segment profit (loss) | 13,438 | 5,180 | 3,049 | (79) |

| | Others | Adjustments | Consolidated results |
|--|--------|-------------|----------------------|
| Net sales Revenue from contracts with customers | 7,696 | _ | 122,115 |
| Other revenues | _ | _ | _ |
| Net sales to external customers | 7,696 | — | 122,115 |
| Intersegment net sales or transfers | 585 | (3,173) | _ |
| Total | 8,281 | (3,173) | 122,115 |
| Segment profit (loss) | 218 | (4,825) | 16,981 |

Notes: 1. Adjustments are as follows.

The (4,825) million yen adjustment in segment profit (loss) includes (2,946) million yen of corporate expenses not allocated to specific reportable segments. Corporate expenses include those of administrative divisions of the Company, such as the general affairs department, that cannot be attributed to any specific reportable segments.

2. Segment profits are adjusted with operating profit under the quarterly consolidated statement of income.

3. Countries / regions in each geographic segment outside Japan.

| (1) The Americas | Mexico, Brazil, The United States of America |
|----------------------|---|
| (2) Asia and Oceania | Hong Kong, China, Indonesia, Singapore, Malaysia, Australia, India, |
| | Vietnam, The United Arab Emirates, Myanmar |
| (3) Europe | The Netherlands, The United Kingdom, Germany, Belgium, Austria, Italy |

2. Changes to reportable segments, etc.

From this first quarter of the current fiscal year, we have changed the presentation of the Pharmaceuticals business, which had previously been presented as a reportable segment, to include it in the Others segment. This was due to the decline in the financial significance of the pharmaceuticals business.

Segment information for the first quarter of the previous fiscal year has been prepared according to the segment categories after the change.

(Significant Subsequent Events)

(Stock Split and Related Partial Amendment to Articles of Incorporation)

The Company resolved at a meeting of its Board of Directors held on July 28, 2023 to carry out a stock split and related partial amendment to the Articles of Incorporation.

1. Stock Split

(1) Purpose of stock split

The purpose of the stock split is to reduce the amount of investment unit of the Company's stock thereby increasing its liquidity and making it easier for investors to invest in the Company.

(2) Outline of stock split

(i) Method of stock split

The Company will implement a 2-for-1 share split of shares in its common stock owned by shareholders listed or recorded in the closing register of shareholders as of the record date of Saturday, September 30, 2023.

(ii) Increase in the number of shares due to stock split

| Total number of shares issued prior to stock split: | 171,045,418 shares |
|---|----------------------|
| Increase in shares from this stock split: | 171,045,418 shares |
| Total number of shares issued following stock split: | 342,090,836 shares |
| Total number of shares authorized to be issued following stock split: | 1,300,000,000 shares |

(iii) Schedule for stock split

| Public notice of record date: | Wednesday, September 13, 2023 |
|-------------------------------|--|
| Record date: | Saturday, September 30, 2023 |
| | *Friday, September 29, 2023, in effect |
| Effective date: | Sunday, October 1, 2023 |

(iv) Effect on information per share

The respective figures in the information per share on the assumption that this share split had been conducted at the beginning of the previous fiscal year are as follows.

| | 1st quarter of previous fiscal year (From April 1, 2022 to June 30, 2022) | 1 st quarter of current fiscal year (From April 1, 2023 to June 30, 2023) |
|--------------------|--|--|
| Quarterly basic | yen | yen |
| earnings per share | 36.52 | 42.00 |

(v) Other

There will be no change in the amount of capital stock on the occasion of this stock split. As the effective date of this stock split will be October 1, 2023, the interim dividend for the fiscal year ending March 31, 2024, which has a record date of September 30, 2023, will be carried out based on the number of shares prior to the stock split.

- 2. Partial Amendment to the Articles of Incorporation Related to Stock Split
 - (1) Reason for the amendment

Along with the stock split, the Company shall change the number of shares it is authorized to issue stipulated in Article 6 of its Articles of Incorporation as of October 1, 2023, in accordance with the provisions of Article 184, Paragraph 2 of the Companies Act.

(2) Details of the amendment

The details of the amendment are as follows.

| | (The amended parts are underlined.) |
|---|---|
| Current Articles of Incorporation | Proposed amendment |
| (Total number of shares authorized to be issued) | (Total number of shares authorized to be issued) |
| Article 6 | Article 6 |
| The total number of shares the Company is | The total number of shares the Company is |
| authorized to issue shall be <u>700,000,000</u> shares. | authorized to issue shall be <u>1,300,000,000</u> shares. |

(3) Schedule of the amendment

Effective date: Sunday, October 1, 2023